EXEL - Exelixis files patent suit against India's Cipla over Cabometyx generics
2024-05-11 15:23:49 ET
More on Exelixis
- Exelixis: With Patent Litigation Decision Due Soon, There Are Options
- Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript
- Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
- Exelixis down 7% as Q1 financial results disappoint
- Exelixis Non-GAAP EPS of $0.17 misses by $0.12, revenue of $425.2M misses by $35.27M